Theravance Biopharma (STU:0TB) Long-Term Capital Lease Obligation : €40.33 Mil (As of Mar. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Theravance Biopharma Long-Term Capital Lease Obligation?

Theravance Biopharma's Long-Term Capital Lease Obligation for the quarter that ended in Mar. 2024 was €40.33 Mil.

Theravance Biopharma's quarterly Long-Term Capital Lease Obligation increased from Sep. 2023 (€38.53 Mil) to Dec. 2023 (€41.48 Mil) but then declined from Dec. 2023 (€41.48 Mil) to Mar. 2024 (€40.33 Mil).

Theravance Biopharma's annual Long-Term Capital Lease Obligation declined from Dec. 2021 (€46.62 Mil) to Dec. 2022 (€42.86 Mil) and declined from Dec. 2022 (€42.86 Mil) to Dec. 2023 (€41.48 Mil).

Theravance Biopharma Long-Term Capital Lease Obligation Historical Data

The historical data trend for Theravance Biopharma's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Theravance Biopharma Long-Term Capital Lease Obligation Chart

Theravance Biopharma Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Long-Term Capital Lease Obligation

Get a 7-Day Free Trial

42.95

38.82

46.62

42.86

41.48

Theravance Biopharma Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Long-Term Capital Lease Obligation	Get a 7-Day Free Trial															40.88	39.25	38.53	41.48	40.33

Theravance Biopharma (STU:0TB) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

Theravance Biopharma Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Theravance Biopharma's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Theravance Biopharma (STU:0TB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Theravance Biopharma Inc (STU:0TB) » Definitions » Long-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

TBPH:USA 0TB:Germany

Address

Ugland House, South Church Street, George Town, PO Box 309, Grand Cayman, CYM, KY1-1104

Website

https://www.theravance.com

Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to better meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

Theravance Biopharma (STU:0TB) Headlines

No Headlines